Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5987MR)

This product GTTS-WQ5987MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5987MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9761MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ577MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ12048MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ2784MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ5942MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ10571MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15243MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ7431MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW